Chest ACCP Education Calendar
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Guest Access | Sign In via User Name/Password
This Article
Right arrow Full Text (PDF) Free
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Article Archive
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Metselaar, H. J.
Right arrow Articles by Weimar, W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Metselaar, H. J.
Right arrow Articles by Weimar, W.

Chest, Vol 97, 396-399, Copyright © 1990 by American College of Chest Physicians

ARTICLES

Cytomegalovirus seronegative heart transplant recipients. Prophylactic use of anti-CMV immunoglobulin

HJ Metselaar, AH Balk, B Mochtar, PH Rothbarth and W Weimar
Department of Internal Medicine, University Hospital Rotterdam- Dijkzigt, The Netherlands.

Thirty-two CMV seronegative heart transplant patients received prophylactic anti-CMV immunoglobulin during the first three posttransplant months. One of the 16 recipients of a heart from a seronegative donor acquired CMV infection and developed CMV disease. In eight of the 16 recipients of a heart from a seropositive donor, CMV infection was observed. Viremia was diagnosed in seven of them, but only two of these patients developed CMV disease. The incidence of CMV infection and of CMV disease in the globulin-treated CMV seronegative recipients of a heart from a seropositive donor was comparable to the incidence of CMV infection and of CMV disease in 31 nonglobulin-treated CMV seropositive recipients. This was significantly lower (percentage difference 69 percent, 95 percent CI 42-97 percent, p less than 0.001) than expected on the basis of the data from the literature and indicates that passive immunization with anti-CMV immunoglobulins induces the same protection against CMV disease as natural acquired anti-CMV resistance. This protective effect was temporary, as one patient developed symptomatic CMV infection four months after transplantation at a time when the anti-CMV immunoglobulin levels had decreased to pretransplantation values.


This article has been cited by other articles:


Home page
 HeartHome page
A. H Balk, P. E Zondervan, P. van der Meer, T. van Gelder, B. Mochtar, M. L Simoons, and W. Weimar
Effect of adopting a new histological grading system of acute rejection after heart transplantation
Heart, December 1, 1997; 78(6): 603 - 607.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
M. E. Wechsler, E.-G. V. Giardina, R. R. Sciacca, E. A. Rose, and M. L. Barr
Increased Early Mortality in Women Undergoing Cardiac Transplantation
Circulation, February 15, 1995; 91(4): 1029 - 1035.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1990 by the American College of Chest Physicians.